Boosting CAR-T cell therapy through vaccine synergy

Various vaccine-based strategies, including mRNA, peptide, viral vector, and dendritic cell platforms, have been explored to enhance chimeric antigen receptor (CAR)-T cell efficacy in targeting cancer, particularly solid tumors. 

Vaccines enhance CAR-T cell efficacy through mechanisms such as presenting CAR antigens to antigen-presenting cells to activate CAR-T cells, promoting a memory-like phenotype in CAR-T cells, modulating the immunosuppressive tumor microenvironment, and reducing tumor cell immune escape.

Clinical outcomes have demonstrated promising efficacy and favorable safety profiles for vaccine-boosted CAR-T cell therapy. Considerations for vaccine manufacturing and clinical translation should encompass key aspects, such as antigen selection and vaccine platform choice, design of vaccination regimens (e.g., dosage and timing), and safety assessments pertaining.

https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(24)00270-0

https://sciencemission.com/CAR-T-cell-therapy-and-vaccine-synergy